In our recent study, we indicated that BMP receptor inhibitors are therapeutic agents that can potentially inhibit the cancer stem cell-related processes in HCC, including tumor progression, recurrence, and metastasis, by inhibiting BMP9-ID1 signaling [9]. This evidence concerns the gene GDF2 and hepatocellular carcinoma.